| __timestamp | Intra-Cellular Therapies, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 5903000 |
| Thursday, January 1, 2015 | 139626 | 2762000 |
| Friday, January 1, 2016 | 93831530 | 1114000 |
| Sunday, January 1, 2017 | 79419009 | 25573000 |
| Monday, January 1, 2018 | 368673 | 6000000 |
| Tuesday, January 1, 2019 | 477121 | 38845000 |
| Wednesday, January 1, 2020 | 1895029 | 50523000 |
| Friday, January 1, 2021 | 8034589 | 75463000 |
| Saturday, January 1, 2022 | 20443000 | 105767000 |
| Sunday, January 1, 2023 | 33745000 | 167512000 |
Unleashing insights
In the dynamic world of biopharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Intra-Cellular Therapies, Inc. and Xenon Pharmaceuticals Inc. from 2014 to 2023. Over this period, Xenon Pharmaceuticals consistently demonstrated a higher cost of revenue, peaking at approximately $168 million in 2023, a staggering 1,700% increase from 2014. In contrast, Intra-Cellular Therapies showed a more volatile pattern, with a notable spike in 2016, reaching nearly $94 million, before stabilizing around $33 million in 2023. This comparison highlights the contrasting financial strategies and operational efficiencies of these two companies. While Xenon Pharmaceuticals appears to invest heavily in its revenue generation, Intra-Cellular Therapies seems to focus on optimizing costs, reflecting different approaches to achieving market success.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Analyzing Cost of Revenue: Novartis AG and Xenon Pharmaceuticals Inc.
Amgen Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Telix Pharmaceuticals Limited vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: PTC Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.